New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Palvella Therapeutics Inc.

Contributing Author

Recent Articles by Palvella Therapeutics Inc.

Oct-13	U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
Sep-24	Palvella Therapeutics Announces Expansion of QTORIN Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies PVLA GlobeNewswire
Sep-17	Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy PVLA GlobeNewswire
Sep-15	Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations PVLA GlobeNewswire
Sep-03	Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer PVLA GlobeNewswire
Aug-28	Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences PVLA GlobeNewswire
Aug-14	Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
Aug-07	Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 PVLA GlobeNewswire
Aug-05	Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference PVLA GlobeNewswire
Jun-30	Palvella Therapeutics Added to Russell 3000 and Russell 2000 Indexes PVLA GlobeNewswire
Jun-23	Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% PVLA GlobeNewswire
Jun-18	Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors PVLA GlobeNewswire
Jun-09	Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations PVLA GlobeNewswire
May-27	Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer PVLA GlobeNewswire
May-15	Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PVLA GlobeNewswire
May-08	Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 PVLA GlobeNewswire
May-05	Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025 PVLA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.